Cervical Cancer Shot Not Cost-Effective for Women in their 20’s

Photo by Getty Images

The results of an intense study performed by the Harvard School of Public Health showed that the expensive cervical cancer shot, Gardasil, was cost-effective for young women in their teens, but not for women in their 20’s. The manufacturer, Merck & Co., wants to market it to women aged 27 and up as a method of “catching up,” but the F.D.A. has rejected their request. This study will undoubtedly strengthen the F.D.A.’s case against Merck’s plans. I’m sure that Merck only wants to market it to us women in our 20’s because they genuinely care… about money!

(story via cnn.com)

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: